215 related articles for article (PubMed ID: 24536001)
21. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy).
Prasto J; Kaplan BS; Russo P; Chan E; Smith RJ; Meyers KE
Eur J Pediatr; 2014 Jun; 173(6):767-72. PubMed ID: 24384791
[TBL] [Abstract][Full Text] [Related]
22. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
23. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
24. Gene polymorphism of complement factor H in a Turkish patient with membranoproliferative glomerulonephritis type II.
Sozeri B; Mir S; Berdeli A; Dincel N; Sarsik B
Iran J Kidney Dis; 2012 Mar; 6(2):149-53. PubMed ID: 22388616
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
27. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
[TBL] [Abstract][Full Text] [Related]
28. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425
[TBL] [Abstract][Full Text] [Related]
29. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
[TBL] [Abstract][Full Text] [Related]
30. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP; Esposito P; Rossini M
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947692
[TBL] [Abstract][Full Text] [Related]
31. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
Ozkaya O; Nalcacioglu H; Tekcan D; Genc G; Meydan BC; Ozdemir BH; Baysal MK; Keceligil HT
Pediatr Nephrol; 2014 Jul; 29(7):1283-7. PubMed ID: 24464478
[TBL] [Abstract][Full Text] [Related]
32. [Clinical approach to primary membranoproliferative glomerulonephritis].
Fakhouri F
Nephrol Ther; 2016 Apr; 12 Suppl 1():S65-9. PubMed ID: 26972096
[TBL] [Abstract][Full Text] [Related]
33. Histopathology of MPGN and C3 glomerulopathies.
Cook HT; Pickering MC
Nat Rev Nephrol; 2015 Jan; 11(1):14-22. PubMed ID: 25447133
[TBL] [Abstract][Full Text] [Related]
34. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
35. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.
Garam N; Prohászka Z; Szilágyi Á; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik-Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Romana Rysava ; Reiterova J; Saraga M; Tomáš Seeman ; Zieg J; Sládková E; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Csuka D
Orphanet J Rare Dis; 2019 Nov; 14(1):247. PubMed ID: 31703608
[TBL] [Abstract][Full Text] [Related]
36. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
Sethi S; Nester CM; Smith RJ
Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
[TBL] [Abstract][Full Text] [Related]
37. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
38. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY.
Trutin I; Oletić L; Galešić Ljubanović D; Turudić D; Milošević D
Acta Clin Croat; 2021 Mar; 60(1):141-145. PubMed ID: 34588735
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.
Li LL; Li ZY; Wang SX; Yu XJ; Tan Y; Wang Y; Yu F; Zhao MH
BMC Nephrol; 2019 Dec; 20(1):459. PubMed ID: 31823738
[TBL] [Abstract][Full Text] [Related]
40. [Changes in the complement system in membranoproliferative glomerulonephritis].
Yurova VA; Bobrova LA; Kozlovskaya NL; Korotchaeva YV; Serova AG; Kozlov LV; Andina SS; Demyanova KA; Kuchieva AM; Roshchupkina SV
Ter Arkh; 2017; 89(6):69-77. PubMed ID: 28745692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]